SLC7A11-independent disulfidptosis induced by a two-pronged delivery strategy for bladder cancer chemotherapy and cisplatin-resistance reverse
Source abstract
Abstract
The intracellular overload of disulfide is induced by the imbalance between cystine (Cys) uptake and intracellular Cys reduction, leading to disulfidptosis. Solute carrier family 7 member 11 (SLC7A11) is a Cys transporter at the cell surface, and its high level of expression, together with glucose deprivation, is a requisite determining the disulfidptosis induction. Recent studies have exploited glucose deprivation by multifunctional nanomaterials as mainstream to evoke disulfidptosis, unfortunately with a strong bias to SLC7A11 highly expressed tumors. Despite many efforts to modulate SLC7A11 expression, the uncertainty brought by complex biological mechanisms under different exposure inspired us to find a more solid approach to raise Cys-uptake efficiency. In this study, we developed a two-pronged approach to deplete glucose and enrich intracellular Cys by co-biomineralizing Cys, glucose oxidase (Gox), and manganese as one entity, further cloaked with tumor cell membrane (M@Cys-Gox-Mn) to enhance tumor-selective uptake. M@Cys-Gox-Mn nanoparticles (NPs) displayed no SLC7A11-dependence for Cys transport and their synergistic action of the dual enzymes enables self-amplifying glucose depletion, thus exacerbating the disulfide stress. The use of M@Cys-Gox-Mn NPs as monotherapy greatly combat orthotopic bladder tumors, and the combination with cisplatin overcome the chemoresistance. Both therapies achieved complete tumor inhibition with favorable biosafety.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Sulfur Compounds in Biology · Cancer, Hypoxia, and Metabolism · Redox biology and oxidative stress
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (22)
Show source-provided references
1. Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis10.1038/s41556-023-01091-2 ↗
2. Disulfidptosis: disulfide stress-induced cell death10.1016/j.tcb.2023.07.009 ↗
3. Disulfidptosis: a new target for metabolic cancer therapy10.1186/s13046-023-02675-4 ↗
4. Programable prodrug nanomodulator targets tumor redox homeostasis imbalance to amplify disulfidptosis and immunogenic pyroptosis for breast tumor immunotherapy10.1002/adhm.202500272 ↗
5. Bioactive nanoliposomes for enhanced sonodynamic-triggered disulfidptosis-like cancer cell death via lipid peroxidation10.2147/IJN.S464178 ↗
6. A novel FTO-Targeting nanodrug induces disulfidptosis and ameliorates the suppressive tumor immune environment to treat uveal melanoma
7. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy, protein
8. Synchronously evoking disulfidptosis and ferroptosis via systematical glucose deprivation targeting SLC7A11/GSH/GPX4 antioxidant axis10.1021/acsnano.5c00730 ↗
9. A multiple-response Cascade nanoreactor for starvation and deep catalysis chemodynamic assisted Near-Infrared-II mild photothermal therapy10.1021/cbmi.2c00003 ↗
10. Biomineralization-inspired synthesis of amorphous manganese phosphates for GLUT5-targeted drug-free catalytic therapy of osteosarcoma10.1039/D1NR06220D ↗
11. Zeta potential and colloidal stability predictions for inorganic nanoparticle dispersions: effects of experimental conditions and electrokinetic models on the interpretation of results10.1021/acs.langmuir.1c02056 ↗
12. Disrupting intracellular homeostasis by copper-based nanoinducer with multiple enzyme-mimicking activities to induce disulfidptosis-enhanced pyroptosis for tumor immunotherapy10.1002/adma.202410957 ↗
13. ZIF-8 nanoparticles evoke pyroptosis for high-efficiency cancer immunotherapy10.1002/anie.202215307 ↗
14. Biomineralized two-enzyme nanoparticles regulate tumor glycometabolism inducing tumor cell pyroptosis and robust antitumor immunotherapy10.1002/adma.202206851 ↗
15. Control of gasdermin D oligomerization and pyroptosis by the Ragulator-Rag-mTORC1 pathway10.1016/j.cell.2021.06.028 ↗
16. SLC7A11 expression level dictates differential responses to oxidative stress in cancer cells10.1038/s41467-023-39401-9 ↗
17. Endocytosis by random initiation and stabilization of clathrin-coated pits10.1016/j.cell.2004.08.017 ↗
18. Caveosomes and endocytosis of lipid rafts10.1242/jcs.00840 ↗
19. Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells10.1038/s41598-021-89684-5 ↗
20. Cancer cell membrane-coated nanoparticles: a promising anti-tumor bionic platform10.1039/D4RA01026D ↗
21. Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms
22. Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A1110.1158/1078-0432.CCR-13-2805 ↗